Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

The U.S. Food and Drug Administration (FDA) has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cancer.

This week in oncology, the FDA expanded the treatment landscape for platinum-resistant ovarian cancer with a new approval, and significant clinical data emerged regarding novel in ...

Treating early-stage prostate cancer was one thing, but Henard’s doctor at the small rural hospital nearby told him the new diagnosis called for a meticulous, highly sophisticated form of treatment.

Lilly denies the claims, which are related to the labeling of a drug some 16 years ago, and has fought the use of so-called RICO statutes as the basis of the case.

As more states legalize marijuana, many people might be wondering if that means it is safe to use. While smoking tobacco is a ...

Jim Hickey, who has survived three cancer diagnoses himself, will walk from Long Island to Staten Island to raise awareness ...

When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...

Adstiladrin may now be thawed in a water bath following an FDA label update, facilitating more efficient treatment delivery for bladder cancer.

A new enforcement action from FDA signals that executive podcast appearances can be regulated like traditional ads when ...